Abivax SA ADR extended gains in after-hours trading, rising 1.3% to $134.95 as investors absorbed fresh Phase 3 data for obefazimod. The late-evening disclosure - filed with the SEC on a Form 6-K and distributed via press release - outlined results from the ABTECT Maintenance Part 2 study, which evaluated continued 50 mg obefazimod in patients with moderately to severely active ulcerative colitis.
The clinical readout showed that, among induction non-responders, 37.2% achieved clinical remission and 34.5% attained endoscopic remission by Week 44 on continued therapy with 50 mg obefazimod. Those efficacy figures applied to a cohort characterized in the release as particularly difficult to treat, and they formed a central part of the market’s positive response.
Equally consequential for sentiment was the expanded integrated Phase 2/3 safety database. According to the company’s disclosure, exposure-adjusted malignancy incidence rates observed across the integrated dataset fell within published background ranges for ulcerative colitis. That safety detail directly addressed cancer-signal concerns that had driven a steep sell-off in the shares in early June and was cited by market participants as a pivotal element behind the stock’s recovery.
Analyst reactions reinforced the rally. Jefferies moved to upgrade Abivax from Hold to Buy and raised its price target to $158 from $108, specifically citing the ABTECT Part 2 safety data as having resolved key investor worries. Guggenheim reiterated its Buy rating and left a $175 price target intact while maintaining Abivax as a Best Idea. Citizens increased its target to $187 and assigned an Outperform rating. Morgan Stanley and Truist trimmed their targets modestly to $132 and $135 respectively, but both sustained positive recommendations, and Barclays continued to rate the shares as a Buy. The cluster of broker actions formed a broad wall of supportive views around the clinical news.
The broader market backdrop also proved constructive. The NASDAQ climbed 1.5% and the S&P 500 rose 0.8% on the session, providing favorable conditions for higher-beta biotech names and helping amplify Abivax’s recovery. The company did not point to any competitor developments as drivers; the movement in the equity was attributed to Abivax’s own pipeline announcement.
Management reaffirmed a near-term regulatory milestone by reiterating plans to submit a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2026. That timeline offers investors a clear event to monitor as the program advances toward potential approval.
Together, the combination of meaningful efficacy in a refractory population, an improved safety narrative across an expanded dataset, an uninterrupted NDA timeline, and coordinated analyst support helped propel the shares back toward the upper portion of their 52-week range. After-hours trading placed the ADR near $134.95, markedly higher than the 52-week low of $7.41 and moving closer to the annual high of $148.83.
Investors will likely continue to track subsequent regulatory filings, updates to the integrated safety database, and any further analyst commentary as the company progresses toward the stated NDA submission window.